Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zynerba Pharma CS (ZYNE)

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 186,744
  • Shares Outstanding, K 23,198
  • Annual Sales, $ 90 K
  • Annual Income, $ -39,910 K
  • 60-Month Beta 4.75
  • Price/Sales 2,255.06
  • Price/Cash Flow N/A
  • Price/Book 2.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.51
  • Number of Estimates 3
  • High Estimate -0.50
  • Low Estimate -0.54
  • Prior Year -0.47
  • Growth Rate Est. (year over year) -8.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.83 +17.86%
on 10/02/19
8.82 -8.73%
on 09/19/19
-0.79 (-8.94%)
since 09/18/19
3-Month
6.83 +17.86%
on 10/02/19
12.51 -35.65%
on 08/21/19
-3.82 (-32.18%)
since 07/18/19
52-Week
2.75 +192.73%
on 12/31/18
16.47 -51.12%
on 05/17/19
+0.76 (+10.43%)
since 10/18/18

Most Recent Stories

More News
Zynerba Pharmaceuticals, Inc. Presenting at the Benzinga Cannabis Capital Conference in Chicago

Chicago, Illinois--(Newsfile Corp. - October 15, 2019) - Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), will be presenting at the 5th Benzinga Cannabis Capital Conference in Chicago October 22-23 before...

CBCA : 0.2600 (-22.27%)
ZYNE : 8.05 (-3.71%)
CBD Use Grows as Nations Relax Restrictions

- FinancialBuzz.com News Commentary

ACB.TO : 4.81 (-5.87%)
ZYNE : 8.05 (-3.71%)
NLB.CN : 0.420 (-5.62%)
CBD Use Grows as Nations Relax Restrictions

The U.S. Drug Enforcement Agency recently announced plans to expand cannabis research after a prolonged delay. The DEA said it hopes to receive a variety of compelling research about marijuana after the...

NLBIF : 0.3440 (-0.29%)
NLB.CN : 0.420 (-5.62%)
ZYNE : 8.05 (-3.71%)
PYX : 12.78 (-1.31%)
ACB : 3.68 (-5.40%)
ACB.TO : 4.81 (-5.87%)
CRON : 8.32 (-6.09%)
Lifshitz & Miller LLP Announces Investigation of Church & Dwight Co., Fibrocell Science, Inc., MacroGenics, Inc., MINDBODY, Inc., PaySign, Inc., Zebra Technologies Corporation and Zynerbia Pharmaceuticals

Church & Dwight Co. (CHD)

CHD : 73.89 (+0.18%)
MGNX : 11.00 (-3.93%)
MB : 36.46 (-0.05%)
PAYS : 11.09 (-0.89%)
ZBRA : 203.06 (-1.30%)
ZYNE : 8.05 (-3.71%)
Cannabis Use Grows as Studies Debunk Old Stereotypes

FinancialBuzz.com News Commentary

ACB.TO : 4.81 (-5.87%)
ZYNE : 8.05 (-3.71%)
CRFT.CN : 0.180 (+5.88%)
Cannabis Use Grows as Studies Debunk Old Stereotypes

Cannabis has been used for medicinal purposes for centuries, but despite the therapeutic benefits of the plant, international regulators ultimately deemed it unsafe for the public due to its marijuana...

CRFTF : 0.1400 (+4.24%)
CRFT.CN : 0.180 (+5.88%)
CRON : 8.32 (-6.09%)
CRON.TO : 10.93 (-5.78%)
ZYNE : 8.05 (-3.71%)
ACB : 3.68 (-5.40%)
ACB.TO : 4.81 (-5.87%)
SNDL : 4.10 (-2.38%)
Zynerba Pharmaceuticals (ZYNE) Stock Moves -1.43%: What You Should Know

Zynerba Pharmaceuticals (ZYNE) closed at $7.26 in the latest trading session, marking a -1.43% move from the prior day.

ZYNE : 8.05 (-3.71%)
Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...

ZYNE : 8.05 (-3.71%)
Epidolex Progresses: Will the Marijuana Drug Market Boom?

Cannabis (or marijuana) based medical products have the potential to become the next booming industry.

GWPH : 118.11 (-0.85%)
ZYNE : 8.05 (-3.71%)
CGC : 20.21 (-2.65%)
ACB : 3.68 (-5.40%)
TLRY : 21.37 (-4.98%)
CRON : 8.32 (-6.09%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zynerba Pharmaceuticals - ZYNE

Pomerantz LLP is investigating claims on behalf of investors of Zynerba Pharmaceuticals ("Zynerba" or the "Company") (NASDAQ: ZYNE). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

ZYNE : 8.05 (-3.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft.

See More Share

Trade ZYNE with:

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

2nd Resistance Point 8.77
1st Resistance Point 8.41
Last Price 8.05
1st Support Level 7.75
2nd Support Level 7.46

See More

52-Week High 16.47
Fibonacci 61.8% 11.23
Fibonacci 50% 9.61
Last Price 8.05
Fibonacci 38.2% 7.99
52-Week Low 2.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar